Winners announced at 2017 Novartis Ophthalmology Case Awards
Apr 05, 2017
Record number of case reports submitted to 2017 16th and 8th Glaucoma and Retina Case Award respectively
A panel of independent experts shortlisted 6 cases in each category to present in person at finals days
Finalists’ cases will be submitted for publication in a peer reviewed journal
Frimley, 4 April, 2017 – The winners of the Novartis Ophthalmology Case Awards were announced last week at a competition judged by a panel of independent medical experts.
Now in its 16th and 8th year respectively, the Novartis Glaucoma and Retina case awards aims to foster and share innovation in the understanding of clinical management of ophthalmic disease within the field of ophthalmology. The award was open to all ophthalmologists in training.
“For me it has been a great privilege to be involved and to have served on the panel of judges at the Novartis National Retina Case awards over the years. Case reports offer great learning opportunities for all of us, from the most junior trainee to the senior specialists as they demonstrate the multitude of ways that a certain disease can present and pose challenges in diagnosis and therapy. For the judges and many delegates who attend this event every year it is a really humbling and inspiring experience to learn from the excellent presentations and the impressive knowledge demonstrated by the finalists,” said Professor Yit Yang, Consultant Ophthalmologist, The Royal Wolverhampton NHS Trust, who has chaired the Retina panel since its incepton in 2009.
“The longevity of the award is a testament to our commitment to foster the next generation of ophthalmologists. As a leader in ophthalmology, we want to continue to innovate for patients and recognise the clinical advances made by the ophthalmology community, “said Dr Dimitrios Georgiopoulos, Chief Scientific Officer at Novartis Pharmaceuticals UK Ltd.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.
In the UK, Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. Based on four sites across the north and south of England, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis by manufacturing the active pharmaceutical ingredients used worldwide in many medicines. In 2015 Novartis in the UK invested over £50million in R&D and is the largest commercial sponsor of clinical trials. For more information, please visit www.novartis.co.uk.